A Phase 2, Randomized, Open-Label, 24-Week Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of GLM101 Administered Intravenously to Adult, Adolescent and Pediatric Participants with PMM2-CDG
This research study is looking into a new medicine called GLM101 for individuals with a rare genetic condition called PMM2-CDG. It's a 'Phase 2' study, which means we're still in the earlier stages of figuring out how well the medicine works and if it's safe. For 24 weeks, researchers will give GLM101 as an injection into the vein to see how the body handles it and its effects. They will closely monitor participants to understand if the medicine helps with movement difficulties, which are common in PMM2-CDG. The main goal is to see if it improves coordination and balance, while also checking for any side effects.
At a glance
What is this study about?
This research study is an important step in trying to find better treatments for PMM2-CDG, a rare genetic disorder that can affect many parts of the body, especially movement and coordination. The study is called 'Phase 2', which means it's one of the first times this new medicine, GLM101, is being tested in a larger group of people. We're looking to understand how the medicine works in the body, confirm it's safe to use, and see if it can help improve some of the challenges people with PMM2-CDG face, particularly with their movement.
Over 24 weeks, participants will receive the study medicine, GLM101, through a drip into their vein. During this time, the research team will regularly check their health and how their body is responding to the medicine. A key part of this study is checking for changes in movement and coordination using a special scoring system. We'll also be very carefully monitoring for any side effects or changes in their general health, including blood tests and heart checks.
The information gathered from this study is crucial. It will help us understand if GLM101 could be a promising new treatment option for PMM2-CDG in the future. If the results are positive, it means we could move closer to making a real difference for people living with this condition.
Key takeaways
- This study tests a new medicine, GLM101, for PMM2-CDG.
- It aims to check if GLM101 is safe and helps with movement.
- Participants will receive the medicine through an IV drip for 24 weeks.
- Regular health checks, blood tests, and movement assessments will be done.
- The study is for adults aged 18 and over with PMM2-CDG.
- This is an 'open-label' study, so you will know you are receiving the active drug.
Who may be eligible?
To join this study, participants must be at least 18 years old. Both men and women are welcome to take part in the research.
Because this study focuses specifically on PMM2-CDG, participants will need to have a confirmed diagnosis of this condition. The study is looking for adults who are able to complete the study assessments.
There might be other health requirements or reasons why someone can't join, which the study doctor will discuss if you're interested. This is to make sure the study is safe for everyone involved and that the results are clear.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I have been diagnosed with PMM2-CDG.
- I am 18 years old or older.
- I am able to attend regular clinic appointments.
- I am not currently pregnant or breastfeeding (if applicable).
What does participation involve?
If you decide to take part in this study, you would receive the study medicine, GLM101, through an intravenous (IV) drip. This means the medicine will be delivered directly into your bloodstream through a small tube in your arm. The treatment period will last for 24 weeks, and during this time, you will have regular visits to the clinic.
During these visits, the research team will perform various checks. These include physical examinations, taking blood and urine samples, checking your heart with an ECG (electrocardiogram), and monitoring your vital signs like blood pressure and heart rate. They will also assess your movement and coordination using specific tests. You'll be asked about how you're feeling and if you've experienced any side effects. After the 24 weeks of treatment, there will be follow-up visits to ensure your continued well-being. The total duration of your involvement, including follow-up, will be explained by the study team.
Potential risks and benefits
Locations (1)
- —UnverifiedSpain
Common questions
What is PMM2-CDG?
PMM2-CDG is a rare genetic condition that can affect many parts of the body, often causing problems with movement and coordination.
What does 'Phase 2' mean?
Phase 2 means this is one of the initial stages of testing a new medicine in people. Researchers are looking closely at its safety and how well it works.
How will the medicine be given?
The medicine, GLM101, will be given through a drip into a vein, usually in your arm.
How long does the study last?
The active treatment part of the study lasts for 24 weeks, with follow-up appointments after that.
Will I know if I'm getting the real medicine?
The study description mentions 'open-label', which means both you and the study team will know you are receiving GLM101, not a dummy treatment.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.